01—Abstract
Summary
Summary of the 10-Q filed May 1, 2024. Cited figures are marked; the original filing is the authoritative source.
United Therapeutics Corporation's first-quarter 2024 Form 10-Q reports total revenues of $677.7 milliona, up from $506.9 million in the first quarter of 2023, with Tyvaso DPI net product sales of $227.5 million and total Tyvaso net product sales of $372.5 million.
Operating income was $356.3 millionb versus $284.4 million a year earlier, and net income was $306.6 million, or $6.17 per diluted share, compared with $240.9 million, or $4.86 per diluted share. Selling, general, and administrative expense rose to $144.4 million from $87.3 million, driven partly by a $31.4 million swing in share-based compensation tied to STAP awards and higher legal expenses. The company repurchased common stock through an accelerated share repurchase agreement with Citibank, making an upfront payment of $1.0 billion and receiving 3,275,199 initial shares.
Total cash, cash equivalents and marketable investments fell to $4,199.7 millionc from $4,903.9 million at year-end 2023, and total stockholders' equity declined to $5,338.1 million from $5,984.8 million. The company paid down $100.0 million on its credit agreement, leaving a $600.0 million outstanding balance, of which $400.0 million is classified as current.
The filing also details extensive litigation, including the ongoing Sandoz contract damages trial that commenced April 29, 2024, multiple patent and regulatory disputes with Liquidia over Yutrepia, and lawsuits from Humana and United Healthcare filed in state court in April 2024. Pipeline milestones include the TETON studies of nebulized Tyvaso in IPF and PPF and the ADVANCE OUTCOMES study of ralinepag, while the company also reports the first xenotransplantation of a UThymoKidney in a living patient in April 2024.
02—Key points
Key Highlights
- Total revenues rose to $677.7 million from $506.9 million, with Tyvaso DPI net product sales of $227.5 million versus $118.7 million a year earlier.
- Net income was $306.6 million, or $6.17 per diluted share, compared with $240.9 million, or $4.86 per diluted share, in the prior-year quarter.
- Selling, general, and administrative expense increased to $144.4 million from $87.3 million, including a share-based compensation expense of $18.1 million versus a benefit of $13.3 million in the prior year.
- The company executed a $1.0 billion accelerated share repurchase agreement with Citibank, reducing stockholders' equity to $5,338.1 million from $5,984.8 million.
- Cash, cash equivalents and marketable investments totaled $4,199.7 million, down from $4,903.9 million at December 31, 2023.
- The credit agreement balance was reduced by $100.0 million to $600.0 million, with $400.0 million classified as a current liability.
- Litigation activity includes the Sandoz breach-of-contract damages trial starting April 29, 2024, the Liquidia Yutrepia patent and FDA disputes, and new Humana and United Healthcare lawsuits filed April 24, 2024.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2024, United Therapeutics kept $0.45.
- Revenue$677.7M100.0%
- Cost of revenue−$72.9M10.8%
- Gross profit$604.8M89.2%
- Operating costs−$248.5M36.7%
- Operating income$356.3M52.6%
- Interest, other & tax−$49.7M7.3%
- Net income$306.6M45.2%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed May 1, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $677.70M$506.90M | +33.7% |
| Cost of Revenue | $72.90M$52.30M | +39.4% |
| Gross Profit | $604.80M$454.60M | +33.0% |
| R&D Expenses | $104.10M$82.90M | +25.6% |
| SG&A Expenses | $144.40M$87.30M | +65.4% |
| Operating Expenses | $321.40M$222.50M | +44.4% |
| Operating Income | $356.30M$284.40M | +25.3% |
| Interest Expense | $13.30M$13.80M | −3.6% |
| Net Income | $306.60M$240.90M | +27.3% |
| EPS (Basic) | $6.52$5.20 | +25.4% |
| EPS (Diluted) | $6.17$4.86 | +27.0% |
| Shares Outstanding (Basic) | 47.00M46.30M | +1.5% |
| Shares Outstanding (Diluted) | 49.70M49.60M | +0.2% |
05—Questions
Frequently Asked Questions
How did revenue and profitability change in the first quarter of 2024?
Total revenues increased to $677.7 million from $506.9 million, and operating income rose to $356.3 million from $284.4 million. Net income increased to $306.6 million from $240.9 million, and diluted earnings per share increased to $6.17 from $4.86. Income tax expense was $92.0 million, and the effective tax rate was 23 percent versus 17 percent a year earlier.
What drove the growth in Tyvaso revenues?
Total Tyvaso net product sales grew 56 percent to $372.5 million, primarily from increased quantities sold following the June 2022 commercial launch of Tyvaso DPI and continued growth in PH-ILD utilization, with a smaller contribution from a price increase. Nebulized Tyvaso net product sales rose to $145.0 million, helped by the absence of distributor destocking that affected the prior-year quarter.
Why did cash and investments decline, and what is the company's debt position?
The decline was primarily due to the $1.0 billion payment to repurchase common stock and a $100.0 million credit line repayment. Cash, cash equivalents and marketable investments totaled $4,199.7 million at March 31, 2024. The outstanding credit agreement balance was $600.0 million, with the credit facility maturing in March 2029, and the company stated it expects to repay $400.0 million within one year.
What are the main litigation and competitive risks disclosed?
The company is in litigation with Sandoz over breach of contract damages, with trial beginning April 29, 2024, and with Liquidia over patents related to Tyvaso DPI and nebulized Tyvaso. On March 28, 2024, the court permitted the FDA to grant final approval for Liquidia's Yutrepia, which the company has moved to stay pending appeal. The filing states that the company cannot reasonably estimate a range of potential losses in the Sandoz matter.
06—Continue